PDF herunterladen
Erfahrungsheilkunde 2013; 62(5): 237-246
DOI: 10.1055/s-0033-1357540
Wissen
© Karl F. Haug Verlag in MVS Medizinverlage Stuttgart GmbH & Co. KG

Basisonkologie in der komplementären Praxis

Stephan Wey
Weitere Informationen

Publikationsverlauf

Publikationsdatum:
24. Oktober 2013 (online)

    Lizenzen und Reprints

Zusammenfassung

Die komplementäre Onkologie bietet eine unüberschaubare Zahl diagnostischer und therapeutischer Möglichkeiten. Die Anwender müssen daher im ärztlichen Alltag im Rahmen persönlicher Erfahrung und wissenschaftlich belastbarer Daten aus Epidemiologie, Grundlagenforschung und Therapie einen schwierigen Weg für den Patienten ebnen. Die Diskussionen mit konventionellen Onkologen zeigen noch zu häufig ungerechtfertigt breite Ablehnung komplementärer Methoden. Zwischen guten Daten einiger Verfahren und einem Abgrenzen weniger wertvoller Verfahren gilt es, eine individuell optimale Therapie für den Krebskranken zu finden und ihn gleichzeitig vor allzu Alternativem zu schützen. Für den begleitenden Hausarzt ist dieser Artikel möglicherweise ein kleiner Leitfaden.

Abstract

The complementary oncology offers a vast number of diagnostic and therapeutic options. The user must therefore in daily medical practice in the context of personal experience and scientifically robust data from epidemiology, basic research and therapy pave a difficult way for the patient. Discussions with conventional oncologists still show too often unjustifiably broad rejection of complementary methods. There is some good data between processes and delimiting a less valuable method of finding individually optimal therapy for cancer patients and to protect it from too alternative. For the accompanying family doctor this article may be a small guide.

Schlüsselwörter

Komplementäre Onkologie - Orthomolekulare Medizin - Hyperthermie - Ernährung - Mistel

Keywords

Complementary oncology - orthomolecular medicine - hyperthermia - nutrition - mistle toe
 

  • Literatur


    • Die Literaturliste finden Sie im Internet unter: www.thieme-connect.de/ejournals
  • 1 Walraven I, Riet E, Stehouwer CDA et al High proinsulin levels are independently associated with 20-year cancer mortality. The Hoorn study Presentation. Poster Nr. 234 bei 49. EASD-Kongress 2013 in Barcelona
    PubMedGoogle Scholar
  • 2 Esposito K, Chiodini P, Colao A et al Metabolic Syndrome and Risk of Cancer − A systematic review and meta-analysis. Diabetes Care 2012; 35: 2402-2411
    CrossrefPubMedGoogle Scholar
  • 3 Gröber U, Mücke R, Adamietz IA et al Komplementärer Einsatz von Antioxidanzien und Mikronährstoffen in der Onkologie. Update 2013. Onkologe 2013; 19: 136-143
    CrossrefPubMedGoogle Scholar
  • 4 Schwaab J, Horisberger K, Erben P. Expression of Transketolase like gene 1 (TKTL1) predicts disease-free survival in patients with locally advanced rectal cancer receiving neoadjuvant chemoradiotherapy. BMC Cancer 2011; 11: 363
    CrossrefPubMedGoogle Scholar
  • 5 Libby G, Donnelly LA, Donnan PT et al New users of metformin are at low risk of incident cancer: a cohort study among people with type 2 diabetes. Diabetes care 2009; 32: 1620-1625
    CrossrefPubMedGoogle Scholar
  • 6 Pantuck AJ, Zomorodian N, Rettig M et al Long term follow up of phase 2 study of pomegranate juice for men with prostate cancer shows durable prolongation of PSA doubling time. J Urology 2009; 181: 295
    PubMedGoogle Scholar
  • 7 Bleys J, Navas-Acien A, Guallar E. Serum selenium levels and all-cause, cancer, and cardiovascular mortality amoung US adults. Arch Intern Med 2008; 168: 404-410
    CrossrefPubMedGoogle Scholar
  • 8 Peters U, Takata Y. Selenium and the prevention of prostate and colorectal cancer. Molecular Nutrition & Food Research 2008; 52: 1261-1272
    CrossrefPubMedGoogle Scholar
  • 9 Mücke R, Schomburg L, Büntzel J. Komplementärer Seleneinsatz in der Onkologie. Onkologe 2010; 16: 181-186
    CrossrefPubMedGoogle Scholar
  • 10 Sieja K, Talerczyk M. Selenium as an element in the treatment of ovarian cancer in women receiving chemotherapy. Gynecol Oncol 2004; 93: 320-327
    CrossrefPubMedGoogle Scholar
  • 11 Asfour IA, El-Tehewi MM, Ahmed MH. High-dose sodium selenite can induce apoptosis of lymphoma cells in adult patients with non-Hodgkin’s lymphoma. Biol Trace Elem Res 2009; 127: 200-210
    CrossrefPubMedGoogle Scholar
  • 12 Lin YS, Lin LC, Lin SW. Effects of zinc supplementation on the survival of patients who received concomitant chemotherapy and radiotherapy for advanced nasopharyngeal carcinoma: follow- up of a double-blind randomized study with subgroup analysis. Laryngoscope 2009; 119: 1348-1352
    CrossrefPubMedGoogle Scholar
  • 13 Lappe JM, Travers-Gustafson D, Davies KM et al Vitamin D and calcium supplementation reduces cancer risk: results of a randomized trial. Am J Clin Nutr 2007; 85: 1586-1591
    PubMedGoogle Scholar
  • 14 Churilla TM, Brereton HD, Klem M. Vitamin D deficiency is widespread in cancer patients and correlates with advanced stage disease: a community oncology experience. Nutr Cancer 2012; 64: 521-525
    CrossrefPubMedGoogle Scholar
  • 15 Drake MT, Maurer MJ, Link BK. Vitamin D insufficiency and prognosis in non-Hodgkin’s lymphoma. J Clin Oncol 2010; 28: 4191-4198
    CrossrefPubMedGoogle Scholar
  • 16 Gorham ED, Garland CF, Garland FC. Optimal vitamin D status for colorectal cancer prevention: a quantitative meta analysis. Am J Prev Med 2007; 32: 210-216
    CrossrefPubMedGoogle Scholar
  • 17 Goodwin PJ, Ennis M, Pritchard KI. Prognostic effects of 25-hydroxyvitamin D levels in early breast cancer. J Clin Oncol 2009; 27: 3757-3763
    CrossrefPubMedGoogle Scholar
  • 18 Schilling S. Epidemic vitamin D deficiency among patients in an elderly care rehabilitation facility. Dtsch Arztebl Int 2012; 109: 33-38
    PubMedGoogle Scholar
  • 19 Santini D, Galluzzo S, Vincenzi B. Longitudinal evaluation of vitamin D plasma levels during anthracycline- and docetaxel-based adjuvant chemotherapy in early-stage breast cancer patients. Ann Oncol 2010; 21: 185-186
    CrossrefPubMedGoogle Scholar
  • 20 Fink M. Vitamin D deficiency is a cofactor of chemotherapy-induced mucocutaneous toxicity and dysgeusia. J Clin Oncol 2011; 29: e81-e82
    CrossrefPubMedGoogle Scholar
  • 21 Prieto-Alhambra D, Javaid MK, Servitja S. Vitamin D threshold to prevent aromatase inhibitor-induced arthralgia: a prospectiv cohort study. Breast Cancer Res Treat 2011; 125: 869-878
    CrossrefPubMedGoogle Scholar
  • 22 Khan QJ, Reddy PS, Kimler BF. Effect of vitamin D supplementation on serum 25-hydroxy vitamin D levels, joint pain, and fatigue in women starting adjuvant letrozole treatment for breast cancer. Breast Cancer Res Treat 2010; 119: 111-118
    CrossrefPubMedGoogle Scholar
  • 23 Roffe L, Schmidt K, Ernst E. Efficacy of Coenzyme Q10 for Improved Tolerability of Cancer Treatments: A Systematic Review. J Clin Oncol 2004; 22: 4418-4424
    CrossrefPubMedGoogle Scholar
  • 24 Konklin KA. Coenzyme Q10 for Prevention of Anthracycline-Induced Cardiotoxicity. Integr Cancer Ther 2005; 4: 110-130
    CrossrefPubMedGoogle Scholar
  • 25 Hall MN, Chavarro JE, Lee IM et al A 22-year prospective study of fish, n-3 fatty acid intake, and colorectal cancer risk in men. Cancer Epidemiol Biomarkers Prev 2008; 17: 1136-1143
    CrossrefPubMedGoogle Scholar
  • 26 Colomer R, Moreno-Nogueira JM, García-Luna PP et al N-3 fatty acids, cancer and cachexia: a systematic review of the literature. Br J Nutr 2007; 97: 823-831
    CrossrefPubMedGoogle Scholar
  • 27 Zhang XH, Ma J, Smith-Warner SA et al Vitamin B6 and colorectal cancer: Current evidence and future directions. World J Gastroenterol 2013; 19: 1005-1010
    CrossrefPubMedGoogle Scholar
  • 28 Jin HW, Flatters SJ, Xiao WH. Prevention of paclitaxel-evoked painful peripheral neuropathy by acetyl-L-carnitine: effects on axonal mitochondria, sensory nerve fiber terminal arbors, and cutaneous Langerhans cells. Exp Neurol 2008; 210: 229-237
    CrossrefPubMedGoogle Scholar
  • 29 Kraft M, Kraft K, Gärtner S et al L-Carnitine-supplementation in advanced pancreatic cancer (CARPAN) − a randomized multicentre trial. Nutr J 2012; 11: 52
    CrossrefPubMedGoogle Scholar
  • 30 Gröber U. Neuroenhancement mit α-Liponsäure. ZKM 2012; 1: 45-49
    PubMedGoogle Scholar
  • 31 Glaudemans B, Knoers NV, Hoenderop JG et al New molecular players facilitating Mg 2+ reabsorption in the distal convoluted tubule. Kidney Int 2010; 77: 17-22
    CrossrefPubMedGoogle Scholar
  • 32 Vormann J. Physiologie und Pathophysiologie von Magnesium. Schw Zeitschr Ernährungsmed 2010; 1: 8-13
    PubMedGoogle Scholar
  • 33 Chen Q, Espey MG, Sun AY et al Pharmacologic doses of ascorbate act as a prooxidant and decrease growth of aggressive tumor xenografts in mice. Proc Natl Acad Sci 2008; 105: 11105-11109
    CrossrefPubMedGoogle Scholar
  • 34 Gröber U, Hübner J, Holzhauer P. Vitamin C in der komplementären Onkologie. Onkologe 2010; 16: 303-313
    PubMedGoogle Scholar
  • 35 Nechuta S, Lu W, Chen Z. Vitamin supplement use during breast cancer treatment and survival: a prospective cohort study. Cancer Epidemiol Biomarkers Prev 2011; 20: 262-271
    CrossrefPubMedGoogle Scholar
  • 36 Vollbracht C, Schneider B, Leendert V. Intravenous vitamin C administration improves quality of life in breast cancer patients during chemo-/radiotherapy and aftercare: results of a retrospective, multicentre, epidemiological cohort study in Germany. In Vivo 2011; 25: 983-990
    PubMedGoogle Scholar
  • 37 Tröger W, Ždrale Z, Stanković N et al Five-year follow-up of patients with early stage breast cancer after a randomized study comparing additional treatment with Viscum album (L.) extract to chemotherapy alone. Breast Cancer: Basic and Clinical Research 2012; 6: 173-180
    PubMedGoogle Scholar
  • 38 Epstein J, Sanderson IR, Macdonald TT. Curcumin as a therapeutic agent: the evidence from in vitro, animal and human studies. Br J Nutr 2010; 103: 1545-1557
    CrossrefPubMedGoogle Scholar
  • 39 Killian PH, Kronski E, Michalik K et al Curcumin Inhibits Prostate Cancer Metastasis in vivo by Targeting the Inflammatory Cytokines CXCL1 and -2. Carcinogenesis 2012; 33: 2507-2519
    CrossrefPubMedGoogle Scholar
  • 40 Sung B, Kunnumakkara AB, Sethi G et al Curcumin circumvents chemoresistance in vitro and potentiates the effect of thalidomide and bortezomib against human multiple myeloma in nude mice model. Mol Cancer Ther 2009; 8: 959-970
    CrossrefPubMedGoogle Scholar
  • 41 Hayun R. Rapamycin and curcumin induce apoptosis in primary resting B chronic lymphocytic leukemia cells. Leuk Lymphoma 2009; 50: 625-632
    CrossrefPubMedGoogle Scholar
  • 42 Sinha D, Biswas J, Sung B et al Chemopreventive and Chemotherapeutic Potential of Curcumin in Breast Cancer. Current Drug Targets 2012; 13: 1799-1819
    CrossrefPubMedGoogle Scholar
  • 43 Nakachi K, Suemasu K, Suga K et al Influence of Drinking Green Tea on Breast Cancer Malignancy among Japanese Patients. Jpn J Cancer Res 1998; 89: 254-261
    CrossrefPubMedGoogle Scholar
  • 44 Sartippour MR, Shao ZM, Heber D et al Green Tea Inhibits Vascular Endothelial Growth Factor (VEGF) Induction in Human Breast Cancer Cells. J Nutr 2002; 132: 2307-2311
    PubMedGoogle Scholar
  • 45 Slivova V, Zaloga G, DeMichele SJ et al Green Tea Polyphenols Modulate Secretion of Urokinase Plasminogen Activator (uPA) and Inhibit Invasive Behavior of Breast Cancer Cells. Nutrition and Cancer 2005; 52: 66-73
    CrossrefPubMedGoogle Scholar
  • 46 Liu FT, Agrawal SG, Movasaghi Z et al Dietary flavonoids inhibit the anti-cancer effects of the proteasome inhibitor Bortezomib. Blood 2008; 112: 3540-3541
    CrossrefPubMedGoogle Scholar
  • 47 Amin AR, Khuri FR, Chen ZG et al Synergistic growth inhibition of squamous cell carcinoma of the head and neck by erlotinib and epigallocatechin-3-gallate: the role of p53-dependent inhibition of nuclear factor-kappaB. Cancer Prev Res 2009; 2: 538-545
    CrossrefPubMedGoogle Scholar
  • 48 Milligan SA, Burke P, Coleman DT et al The green tea polyphenol EGCG potentiates the antiproliferative activity of c-Met and epidermal growth factor receptor inhibitors in non-small cell lung cancer cells. Clin Cancer Res 2009; 15: 4885-4894
    CrossrefPubMedGoogle Scholar
  • 49 Brausi M, Rizzi F, Bettuzzi S. Chemoprevention of human prostate cancer by green tea catechins: two years later. A follow-up update. European Urology 2008; 54: 472-473
    CrossrefPubMedGoogle Scholar
  • 50 Böker DK, Winking M. Die Rolle von Boswellia-Säuren in der Therapie maligner Gliome. Dt Ärztebl 1997; 94: A-1197-1199
    PubMedGoogle Scholar
  • 51 Kirste S, Trier M, Wehrle SJ et al Boswellia serrata acts on cerebral edema in patients irradiated for brain tumors. Cancer 2011; 117: 3788-3795
    CrossrefPubMedGoogle Scholar
  • 52 Singh RP, Agarwal R. Prostate cancer chemoprevention by silibinin: Bench to bedside. Carcinogenesis 2006; 45: 436-442
    CrossrefPubMedGoogle Scholar
  • 53 JM Wallace Nutritional and Botanical Modulation of the Inflammatory Cascade−Eicosanoids, Cyclooxygenases, and Lipoxygenases − As an Adjunct in Cancer Therapy. Integr Cancer Ther 2002; 1: 7-37
    PubMedGoogle Scholar
  • 54 Kallifatidis G, Rausch V, Baumann B et al Sulforaphane targets pancreatic tumor-initiating cells by NF-κB-induced anti-apoptotic signaling. GUT 2009; 58: 949-963
    CrossrefPubMedGoogle Scholar
  • 55 Beuth J. Proteolytic enzyme therapy in evidence-based complementary oncology: fact or fiction?. Integr Cancer Ther 2008; 7: 311-316
    CrossrefPubMedGoogle Scholar
  • 56 Gebauer F, Micheel B, Stauder G et al Proteolytic Enzymes Modulate the Adhesion Molecule CD44 on Malignant Cells in Vitro. Int. J. Immunotherapy 1997; 13: 111-119
    PubMedGoogle Scholar
  • 57 Stoll G. Thymuspeptide in der Onkologie. Z Onkol 1999; 31: 1-7
    PubMedGoogle Scholar
  • 58 Kindler M. Factor AF2 als Begleitmaßnahme zur Chemotherapie − myeloprotektive und antiemetische Wirkungen. Z Onkol 1997; 29: 7-10
    PubMedGoogle Scholar
  • 59 Matsumoto S. Cimetidine increases survival of colorectal cancer patients with high levels of sialyl Lewis-X and sialyl Lewis − A epitope expression on tumour cells. British Journal of Cancer 2002; 86: 161-167
    CrossrefPubMedGoogle Scholar
  • 60 Li B, Cao F, Zhu Q et al Perioperative Cimetidine Administration Improves Systematic Immune Response and Tumor Infiltrating Lymphocytes in Patients with Colorectal Cancer. Hepatogastroenterology 2013; 60: 244-247
    PubMedGoogle Scholar
  • 61 Lefranc F, Yeaton P, Brotchi J et al Cimetidine, an unexpected anti-tumor agent, and its potential for the treatment of glioblastoma. Int J Oncol 2006; 28: 1021-1030
    PubMedGoogle Scholar
  • 62 Calderwood SK, Murshid A, Gong J. Heat Shock Proteins: Conditional Mediators of Inflammation in Tumor Immunity. Front Immunol 2012; 3: 75
    PubMedGoogle Scholar
  • 63 Multhoff G, Radons J. Radiation, Inflammation, and Immune Responses in Cancer. Front Oncol 2012; 2: 58
    PubMedGoogle Scholar
  • 64 Wust P, Hildebrandt B, Sreenivasa G et al Hyperthermia in combined treatment of cancer. The Lancet Oncology 2002; 3: 487-497
    CrossrefPubMedGoogle Scholar
  • 65 Hager ED, Dziambor H, Höhmann D et al Intraperitoneal hyperthermic perfusion chemotherapy of patients with chemotherapy-resistant peritoneal disseminated ovarian cancer. Int J Gynecol Cancer 2001; 11: 57-63
    CrossrefPubMedGoogle Scholar
  • 66 Bojko P, Schimmel G, Bosse D et al Metronomic Oral Cyclophosphamide in Patients with Advanced Solid Tumors. Onkologie 2012; 35: 35-38
    CrossrefPubMedGoogle Scholar
  • 67 Mills E, Wu P, Seely D et al Melatonin in the treatment of cancer: a systematic review of randomized controlled trials and meta-analysis. Journal of Pineal Research 2005; 39: 360-366
    CrossrefPubMedGoogle Scholar
  • 68 Harris RE, Beebe-Donk J, Doss H et al Aspirin, ibuprofen, and other non-steroidal anti-inflammatory drugs in cancer prevention: A critical review of non-selective COX-2 blockade. Oncology Reports 2005; 13: 559-583
    PubMedGoogle Scholar
  • 69 Rothwell PM. Aspirin in Prevention of Sporadic Colorectal Cancer: Current Clinical Evidence and Overall Balance of Risks and Benefits. Prospects for Chemoprevention of Colorectal Neoplasia: Recent Results in Cancer Research 2013 191. 121-142
    PubMedGoogle Scholar
  • 70 Potter GA, Burke MD. Salvestrols − Natural Products with Tumor Selective Activity. J Orthomol Med 2006; 21: 34-36
    PubMedGoogle Scholar
  • 71 Michelakis ED, Webster L, Mackey JR. Dichloroacetate (DCA) as a potential metabolic-targeting therapy for cancer. Br J Cancer 2008; 99: 989-994
    CrossrefPubMedGoogle Scholar
  • 72 Lever JR. Opioid Receptors and Ligands: Targets for Cancer Imaging and Therapy. Med Chem 2012; 2: 142-147
    PubMedGoogle Scholar
  • 73 Hagenbeck C, Krawcyk N, Melcher C et al Zirkulierende Tumorzellen − bereits klinische Routine oder noch Forschungsobjekt?. Deutsche Zeitschrift für Onkologie 2013; 45: 55-61
    Artikel in Thieme ConnectPubMedGoogle Scholar